nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2024-1S-4-11nnp-2370Research ArticleLECTURESЛЕКЦИЯGastric stasis in migraine and the efficacy of antimigraine drugsГастростаз при мигрени и эффективность противомигренозных средствhttps://orcid.org/0000-0002-3833-532XТабееваГ. Р.TabeevaG. R.

Гюзяль Рафкатовна Табеева

Москва, 119021, Москва, ул. Россолимо, 11, стр. 1

Guzyal Rafkatovna Tabeeva

Moscow 11, Rossolimo St., Build. 1, Moscow 119021

grtabeeva@gmail.comhttps://orcid.org/0009-0002-4678-3349ХаритоноваА. А.KharitonovaA. A.

Москва, 119021, Москва, ул. Россолимо, 11, стр. 1

Moscow 11, Rossolimo St., Build. 1, Moscow 119021

Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияDepartment of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian Federation202419102024161SСпецвыпуск: Головная боль411Copyright © Tabeeva G.R., Kharitonova A.A., 20242024Табеева Г.Р., Харитонова А.А.Tabeeva G.R., Kharitonova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2370

Migraine is characterized by severe headache attacks with the development of accompanying symptoms. Among the most common are nausea and vomiting, which limit the intake of oral medications and thus reduce the speed of onset of pain relief and the efficacy of treatment in general. The development of gastric stasis in migraine is considered to be one of the most important reasons for the delayed absorption and inconsistent effect of oral triptans. The rapid action of triptans in the form of orally dispersible tablets, efficacy in relieving pain and accompanying symptoms, and ease of administration make this form favorable as a first-line agent for the relief of migraine attacks.

Мигрень характеризуется приступами тяжелой головной боли с развитием сопровождающих симптомов. Среди них наиболее частыми являются тошнота и рвота, которые ограничивают прием пероральных лекарственных средств, снижая скорость наступления обезболивания и эффективность лечения в целом. Развитие гастростаза при мигрени рассматривают в качестве одной из важных причин задержки абсорбции и непостоянства эффектов пероральных триптанов. Быстрое действие триптанов в форме ородиспергируемых таблеток, эффективность купирования как боли, так и сопровождающих симптомов, а также удобство применения делают эту форму предпочтительной в качестве средства первого выбора для купирования приступов мигрени.

мигренькупирование приступовтриптаныризатриптанородиспергируемые таблеткиmigrainerelief of attackstriptansrizatriptanorally dispersible tabletsReferencesWillis T, Pordage S. Two Discourses Concerning the Soul of Brutes, Which Is That of the Vital and Sensitive of Man: The First Is Physiological, Shewing the Nature, Parts, Powers, and Affections of the Same; and the Other Is Pathological, Which Unfolds the Diseases which Affect It and Its Primary Seat, to Wit, the Brain and Nervous Stock, and Treats of Their Cures: With Copper Cuts; Thomas Dring, Ch. Harper and John Leigh. London, UK; 1683. doi: 10.1037/11794-000Willis T, Pordage S. Two Discourses Concerning the Soul of Brutes, Which Is That of the Vital and Sensitive of Man: The First Is Physiological, Shewing the Nature, Parts, Powers, and Affections of the Same; and the Other Is Pathological, Which Unfolds the Diseases which Affect It and Its Primary Seat, to Wit, the Brain and Nervous Stock, and Treats of Their Cures: With Copper Cuts; Thomas Dring, Ch. Harper and John Leigh. London, UK; 1683. doi: 10.1037/11794-000Villar-Martinez MD, Goadsby PJ. Pathophysiology and Therapy of Associated Features of Migraine. Cells. 2022 Sep 5;11(17):2767. doi: 10.3390/cells11172767Villar-Martinez MD, Goadsby PJ. Pathophysiology and Therapy of Associated Features of Migraine. Cells. 2022 Sep 5;11(17):2767. doi: 10.3390/cells11172767Goadsby PJ, Holland PR. An Update: Pathophysiology of Migraine. Neurol Clin. 2019 Nov;37(4):651-71. doi: 10.1016/j.ncl.2019.07.008Goadsby PJ, Holland PR. An Update: Pathophysiology of Migraine. Neurol Clin. 2019 Nov;37(4):651-71. doi: 10.1016/j.ncl.2019.07.008Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202Munjal S, Singh P, Reed ML, et al. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. Headache. 2020 Feb;60(2):416-29. doi: 10.1111/head.13708. Epub 2019 Dec 14.Munjal S, Singh P, Reed ML, et al. Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. Headache. 2020 Feb;60(2):416-29. doi: 10.1111/head.13708. Epub 2019 Dec 14.Kim BK, Chu MK, Yu SJ, et al. Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021 May 24;22(1):45. doi: 10.1186/s10194-021-01250-6Kim BK, Chu MK, Yu SJ, et al. Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021 May 24;22(1):45. doi: 10.1186/s10194-021-01250-6Lipton RB, Buse DC, Saiers J, et al. Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. J Med Econ. 2013;16(4):490-9. doi: 10.3111/13696998.2013.770748Lipton RB, Buse DC, Saiers J, et al. Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. J Med Econ. 2013;16(4):490-9. doi: 10.3111/13696998.2013.770748Gajria K, Lee LK, Flores NM, et al. Humanistic and economic burden of nausea and vomiting among migraine sufferers. J Pain Res. 2017 Mar 24;10:689-98. doi: 10.2147/JPR.S124683Gajria K, Lee LK, Flores NM, et al. Humanistic and economic burden of nausea and vomiting among migraine sufferers. J Pain Res. 2017 Mar 24;10:689-98. doi: 10.2147/JPR.S124683Lipton RB, Buse DC, Saiers J, et al. Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013 Jan;53(1):93-103. doi: 10.1111/j.1526-4610.2012.02292.x. Epub 2012 Nov 13.Lipton RB, Buse DC, Saiers J, et al. Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013 Jan;53(1):93-103. doi: 10.1111/j.1526-4610.2012.02292.x. Epub 2012 Nov 13.Kovacic K, Li BUK. Cyclic vomiting syndrome: A narrative review and guide to management. Headache. 2021 Feb;61(2):231-43. doi: 10.1111/head.14073. Epub 2021 Feb 23.Kovacic K, Li BUK. Cyclic vomiting syndrome: A narrative review and guide to management. Headache. 2021 Feb;61(2):231-43. doi: 10.1111/head.14073. Epub 2021 Feb 23.Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil. 2019 Jun;31(Suppl 2):e13604. doi: 10.1111/nmo.13604Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil. 2019 Jun;31(Suppl 2):e13604. doi: 10.1111/nmo.13604Abouzari M, Cheung D, Pham T, et al. The Relationship Between Vestibular Migraine and Motion Sickness Susceptibility. Otol Neurotol. 2020 Sep;41(8):1116-21. doi: 10.1097/MAO.0000000000002705Abouzari M, Cheung D, Pham T, et al. The Relationship Between Vestibular Migraine and Motion Sickness Susceptibility. Otol Neurotol. 2020 Sep;41(8):1116-21. doi: 10.1097/MAO.0000000000002705Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a doubleblind, placebo-controlled pilot study. Med Sci Monit. 2006 Jan;12(1):PI1-7. Epub 2005 Dec 19.Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a doubleblind, placebo-controlled pilot study. Med Sci Monit. 2006 Jan;12(1):PI1-7. Epub 2005 Dec 19.Aurora SK, Papapetropoulos S, Kori SH, et al. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013 Apr;33(6):408- 15. doi: 10.1177/0333102412473371Aurora SK, Papapetropoulos S, Kori SH, et al. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013 Apr;33(6):408- 15. doi: 10.1177/0333102412473371Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001 JulAug;41(7):646-57. doi: 10.1046/j.1526-4610.2001.041007646.xLipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001 JulAug;41(7):646-57. doi: 10.1046/j.1526-4610.2001.041007646.xWaseem S, Moshiree B, Draganov PV. Gastroparesis: current diagnostic challenges and management considerations. World J Gastroenterol. 2009 Jan 7;15(1):25-37. doi: 10.3748/wjg.15.25Waseem S, Moshiree B, Draganov PV. Gastroparesis: current diagnostic challenges and management considerations. World J Gastroenterol. 2009 Jan 7;15(1):25-37. doi: 10.3748/wjg.15.25Jung HK, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225-33. doi: 10.1053/j.gastro.2008.12.047Jung HK, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225-33. doi: 10.1053/j.gastro.2008.12.047Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995–2004. Am J Gastroenterol. 2008 Feb;103(2):313-22. doi: 10.1111/j.1572-0241.2007.01658.x. Epub 2007 Nov 28.Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995–2004. Am J Gastroenterol. 2008 Feb;103(2):313-22. doi: 10.1111/j.1572-0241.2007.01658.x. Epub 2007 Nov 28.Parkman HP. Migraine and gastroparesis from a gastroenterologist's perspective. Headache. 2013 Jun;53 Suppl 1:4-10. doi: 10.1111/head.12112Parkman HP. Migraine and gastroparesis from a gastroenterologist's perspective. Headache. 2013 Jun;53 Suppl 1:4-10. doi: 10.1111/head.12112Peroutka SJ. Migraine: a chronic sympathetic nervous system disorder. Headache. 2004 Jan;44(1):53-64. doi: 10.1111/j.1526-4610.2004.04011.xPeroutka SJ. Migraine: a chronic sympathetic nervous system disorder. Headache. 2004 Jan;44(1):53-64. doi: 10.1111/j.1526-4610.2004.04011.xArslan D, Ünal Cevik I. Interactions between the painful disorders and the autonomic nervous system. Agri. 2022 Jul;34(3):155-65. doi: 10.14744/agri.2021.43078Arslan D, Ünal Cevik I. Interactions between the painful disorders and the autonomic nervous system. Agri. 2022 Jul;34(3):155-65. doi: 10.14744/agri.2021.43078Arca KN, Cai J, Wang F, et al. Migraine and Gastroparesis. Curr Neurol Neurosci Rep. 2022 Dec;22(12):813-21. doi: 10.1007/s11910-022-01241-3Arca KN, Cai J, Wang F, et al. Migraine and Gastroparesis. Curr Neurol Neurosci Rep. 2022 Dec;22(12):813-21. doi: 10.1007/s11910-022-01241-3Miglis MG. Migraine and Autonomic Dysfunction: Which Is the Horse and Which Is the Jockey? Curr Pain Headache Rep. 2018 Feb 23;22(3):19. doi: 10.1007/s11916-018-0671-yMiglis MG. Migraine and Autonomic Dysfunction: Which Is the Horse and Which Is the Jockey? Curr Pain Headache Rep. 2018 Feb 23;22(3):19. doi: 10.1007/s11916-018-0671-yAurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006 Jan;46(1):57-63. doi: 10.1111/j.1526-4610.2006.00311.xAurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006 Jan;46(1):57-63. doi: 10.1111/j.1526-4610.2006.00311.xTang DM, Friedenberg FK. Gastroparesis: Approach, diagnostic evaluation, and management. Dis Mon. 2011;57:74-101. doi: 10.1016/j.disamonth.2010.12.007Tang DM, Friedenberg FK. Gastroparesis: Approach, diagnostic evaluation, and management. Dis Mon. 2011;57:74-101. doi: 10.1016/j.disamonth.2010.12.007Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010; 24:929-40 doi: 10.2165/11317540-000000000-00000Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010; 24:929-40 doi: 10.2165/11317540-000000000-00000Ferrari A, Tiraferri I, Neri L, Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain. 2011 Feb;12(1):5- 12. doi: 10.1007/s10194-010-0258-4Ferrari A, Tiraferri I, Neri L, Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain. 2011 Feb;12(1):5- 12. doi: 10.1007/s10194-010-0258-4Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migrainefree period. Cephalalgia. 1996 Jun;16(4):270-5. doi: 10.1046/j.1468-2982.1996.1604270.xThomsen LL, Dixon R, Lassen LH, et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migrainefree period. Cephalalgia. 1996 Jun;16(4):270-5. doi: 10.1046/j.1468-2982.1996.1604270.xAurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007 Nov- Dec;47(10):1443-6. doi: 10.1111/j.1526-4610.2007.00922.xAurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007 Nov- Dec;47(10):1443-6. doi: 10.1111/j.1526-4610.2007.00922.xTokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67-75. doi: 10.1111/j.1365-2125.1984.tb05001.xTokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67-75. doi: 10.1111/j.1365-2125.1984.tb05001.xBoyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990;30:405-9. doi: 10.1111/j.1365-2125.1990.tb03791.xBoyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990;30:405-9. doi: 10.1111/j.1365-2125.1990.tb03791.xHasler WL. Gastroparesis: Pathogenesis, diagnosis, and management. Nat Rev Gastroenterol Hepatol. 2011;8:438-53. doi: 10.1038/nrgastro.2011.116Hasler WL. Gastroparesis: Pathogenesis, diagnosis, and management. Nat Rev Gastroenterol Hepatol. 2011;8:438-53. doi: 10.1038/nrgastro.2011.116Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019 Dec;68(12):2238-50. doi: 10.1136/gutjnl-2019-318712Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019 Dec;68(12):2238-50. doi: 10.1136/gutjnl-2019-318712Patil CS, Singh VP, Jain NK, Kulkarni SK. Inhibitory effect of sildenafil on gastrointestinal smooth muscle: role of NO-cGMP transduction pathway. Indian J Exp Biol. 2005 Feb;43(2):167-71.Patil CS, Singh VP, Jain NK, Kulkarni SK. Inhibitory effect of sildenafil on gastrointestinal smooth muscle: role of NO-cGMP transduction pathway. Indian J Exp Biol. 2005 Feb;43(2):167-71.Kaufman J, Levine I. Acute gastric dilatation of stomach during attack of migraine. Radiology. 1936;27:301-5.Kaufman J, Levine I. Acute gastric dilatation of stomach during attack of migraine. Radiology. 1936;27:301-5.Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol. 1984;18:867-71. doi: 10.1111/j.1365-2125.1984.tb02557.xTokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol. 1984;18:867-71. doi: 10.1111/j.1365-2125.1984.tb02557.xYalcin H, Okuyucu EE, Ucar E, et al. Changes in liquid emptying in migraine patients: diagnosed with liquid phase gastric emptying scintigraphy. Intern Med J. 2012 Apr;42(4):455-9. doi: 10.1111/j.1445-5994.2012.02741.xYalcin H, Okuyucu EE, Ucar E, et al. Changes in liquid emptying in migraine patients: diagnosed with liquid phase gastric emptying scintigraphy. Intern Med J. 2012 Apr;42(4):455-9. doi: 10.1111/j.1445-5994.2012.02741.xLadabaum U, Hasler WL. Novel approaches to the treatment of nausea and vomiting. Dig Dis. 1999;17(3):125-32. doi: 10.1159/000016917Ladabaum U, Hasler WL. Novel approaches to the treatment of nausea and vomiting. Dig Dis. 1999;17(3):125-32. doi: 10.1159/000016917Soffer E, Abell T, Lin Z, et al. Review article: Gastric electrical stimulation for gastroparesis – physiological foundations, technical aspects and clinical implications. Aliment Pharmacol Ther. 2009;30:681-94. doi: 10.1111/j.1365-2036.2009.04082.xSoffer E, Abell T, Lin Z, et al. Review article: Gastric electrical stimulation for gastroparesis – physiological foundations, technical aspects and clinical implications. Aliment Pharmacol Ther. 2009;30:681-94. doi: 10.1111/j.1365-2036.2009.04082.xChristensen CJ, Johnson WD, Abell TL. Patients with cyclic vomiting pattern and diabetic gastropathy have more migraines, abnormal electrogastrograms, and gastric emptying. Scand J Gastroenterol. 2008;43:1076-81. doi: 10.1080/00365520802085411Christensen CJ, Johnson WD, Abell TL. Patients with cyclic vomiting pattern and diabetic gastropathy have more migraines, abnormal electrogastrograms, and gastric emptying. Scand J Gastroenterol. 2008;43:1076-81. doi: 10.1080/00365520802085411Nyholm D, Lennernäs H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol. 2008;4:193-203. doi: 10.1517/17425255.4.2.193Nyholm D, Lennernäs H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol. 2008;4:193-203. doi: 10.1517/17425255.4.2.193Volans GN. Absorption of effervescent aspirin during migraine. Br Med J. 1974;4:265- 8. doi: 10.1136/bmj.4.5939.265Volans GN. Absorption of effervescent aspirin during migraine. Br Med J. 1974;4:265- 8. doi: 10.1136/bmj.4.5939.265Sramek JJ, Hussey EK, Clements B, et al. Oral sumatriptan pharmacokinetics in the migraine state. Clin Drug Invest. 1999;17:137-44.Sramek JJ, Hussey EK, Clements B, et al. Oral sumatriptan pharmacokinetics in the migraine state. Clin Drug Invest. 1999;17:137-44.Cutler NR, Jhee SS, Majumdor AK. Pharmacokinetics of rizatriptan tablets during and between migraine attacks. Headache. 1999;39:264-9. doi: 10.1046/j.1526-4610.1999.3904264.xCutler NR, Jhee SS, Majumdor AK. Pharmacokinetics of rizatriptan tablets during and between migraine attacks. Headache. 1999;39:264-9. doi: 10.1046/j.1526-4610.1999.3904264.xHaberer LJ, Walls CM, Lener SE. Distinct pharmacokinetic profile and safety of a fixeddose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010;50:357-73 doi: 10.1111/j.1526-4610.2009.01606.xHaberer LJ, Walls CM, Lener SE. Distinct pharmacokinetic profile and safety of a fixeddose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010;50:357-73 doi: 10.1111/j.1526-4610.2009.01606.xPini CA, Bertolotti M, Bergonzani G. Pharmacokinetics of tiaprofenic acid after oral administration in fasting patients during and between migraine attacks. Headache. 1990;30:672-5. doi: 10.1111/j.1526-4610.1990.hed3010672.xPini CA, Bertolotti M, Bergonzani G. Pharmacokinetics of tiaprofenic acid after oral administration in fasting patients during and between migraine attacks. Headache. 1990;30:672-5. doi: 10.1111/j.1526-4610.1990.hed3010672.xPini CA, Bertolotti M, Trenti T. Disposition of naproxen after oral administration during and between migraine attacks. Headache. 1993;33:181-94. doi: 10.1111/j.1526-4610.1993.hed33040191.xPini CA, Bertolotti M, Trenti T. Disposition of naproxen after oral administration during and between migraine attacks. Headache. 1993;33:181-94. doi: 10.1111/j.1526-4610.1993.hed33040191.xТабеева ГР. Проблемы выбора эффективного обезболивания при мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(5):109-16. doi: 10.14412/2074-2711-2023-5-109-116 doi: 10.14412/2074-2711-2023-5-109-116Tabeeva GR. Problems in the selection of effective analgesics for migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(5):109-16. doi: 10.14412/2074-2711-2023-5-109-116 (In Russ.).Жмылёва ПВ, Табеева ГР. Мигрень и ее эквиваленты детского возраста. Неврология, нейропсихиатрия, психосоматика. 2023;15(6):10-7. doi: 10.14412/2074-2711-2023-6-10-17Zhmyleva PV, Tabeeva GR. Migraine and its childhood equivalents. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(6):10- 7. doi: 10.14412/2074-2711-2023-6-10-17 (In Russ.).Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A doubleblind, randomized, crossover, placebo-controlled study. Cephalalgia. 2006;26:871-4. doi: 10.1111/j.1468-2982.2006.01136.xKrymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A doubleblind, randomized, crossover, placebo-controlled study. Cephalalgia. 2006;26:871-4. doi: 10.1111/j.1468-2982.2006.01136.xWainscott G, Kaspi T, Volans GN. The influence of effervescent aspirin in migraine. Br J Clin Pharmacol. 1976;3:1015-21. doi: 10.1111/j.1365-2125.1976.tb00351.xWainscott G, Kaspi T, Volans GN. The influence of effervescent aspirin in migraine. Br J Clin Pharmacol. 1976;3:1015-21. doi: 10.1111/j.1365-2125.1976.tb00351.xTfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A double-blind study. Cephalalgia. 1984;4:107- 11. doi: 10.1046/j.1468-2982.1984.0402107.xTfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A double-blind study. Cephalalgia. 1984;4:107- 11. doi: 10.1046/j.1468-2982.1984.0402107.xTokola RA, Kangasniemi P, Neuvonen PJ. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia. 1984;4:253-63. doi: 10.1046/j.1468-2982.1984.0404253.xTokola RA, Kangasniemi P, Neuvonen PJ. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia. 1984;4:253-63. doi: 10.1046/j.1468-2982.1984.0404253.xMacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13:124-7. doi: 10.1046/j.1468-2982.1993.1302124.xMacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13:124-7. doi: 10.1046/j.1468-2982.1993.1302124.xEvers S, Afra S, Frese A. EFNS guideline on drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16:968- 81. doi: 10.1111/j.1468-1331.2009.02748.xEvers S, Afra S, Frese A. EFNS guideline on drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16:968- 81. doi: 10.1111/j.1468-1331.2009.02748.xWorthington I. Delivery systems for acute migraine medications. Can Fam Physician. 2001;47:322-9.Worthington I. Delivery systems for acute migraine medications. Can Fam Physician. 2001;47:322-9.Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133 (In Russ.).Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116Sergeev AV, Tabeeva GR, Filatova EG, et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116 (In Russ.).Bentivegna E, Galastri S, Onan D, Martelletti P. Unmet Needs in the Acute Treatment of Migraine. Adv Ther. 2024;41:1-13. doi: 10.1007/s12325-023-02650-7Bentivegna E, Galastri S, Onan D, Martelletti P. Unmet Needs in the Acute Treatment of Migraine. Adv Ther. 2024;41:1-13. doi: 10.1007/s12325-023-02650-7Sacco S, Braschinsky M, Ducros A, et al. European Headache Federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76. doi: 10.1186/s10194-020-01130-5Sacco S, Braschinsky M, Ducros A, et al. European Headache Federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76. doi: 10.1186/s10194-020-01130-5Табеева ГР, Косивцова ОВ, Ковальчук НА, Орлюк ТА. Рефрактерная мигрень. Неврология, нейропсихиатрия, психосоматика. 2024;16(2):76-86. doi: 10.14412/2074-2711-2024-2-76-86Tabeeva GR, Kosivtsova OV, Kovalchuk NA, Orlyuk TA. Refractory migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):76- 86. doi: 10.14412/2074-2711-2024-2-76-86 (In Russ.).Leroux E, Buchanan A, Lombard L, et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther. 2020;37:4765-96. doi: 10.1007/s12325-020-01494-9Leroux E, Buchanan A, Lombard L, et al. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review. Adv Ther. 2020;37:4765-96. doi: 10.1007/s12325-020-01494-9Lombard L, Farrar M, Ye W. A global realworld assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41. doi: 10.1186/s10194-020-01110-9Lombard L, Farrar M, Ye W. A global realworld assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41. doi: 10.1186/s10194-020-01110-9Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376- 88. doi: 10.1046/j.1526-4610.2003.03073.xGeraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376- 88. doi: 10.1046/j.1526-4610.2003.03073.xSeeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011;31(7):786- 96. doi: 10.1177/0333102410390399Seeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011;31(7):786- 96. doi: 10.1177/0333102410390399Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache. 2000;40(6):464-5. doi: 10.1046/j.1526-4610.2000.00069.xMathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache. 2000;40(6):464-5. doi: 10.1046/j.1526-4610.2000.00069.xТабеева ГР, Косивцова ОВ. Современные стратегии лечения приступа мигрени и возможности дифференцированного подхода. Медицинский Совет. 2023;(21):54- 62. doi: 10.21518/ms2023-425Tabeeva GR, Kosivtsova OV. Modern strategies for the treatment of migraine attacks and the possibility of a differentiated approach. Meditsinskiy sovet = Medical Council. 2023;(21):54-62. doi: 10.21518/ms2023-425 (In Russ.).Lombard L, Schroeder K, Nichols R, et al. Characteristics, treatment patterns, and healthcare resource utilization in patients with migraine who initiated a triptan. Headache. 2018;58(S2):182-3. doi: 10.1111/head.13835Lombard L, Schroeder K, Nichols R, et al. Characteristics, treatment patterns, and healthcare resource utilization in patients with migraine who initiated a triptan. Headache. 2018;58(S2):182-3. doi: 10.1111/head.13835Diener HC, Tassorelli C, Dodick DW, et al; International Headache Society Clinical Trials Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020 Sep;40(10):1026-44. doi: 10.1177/0333102420941839Diener HC, Tassorelli C, Dodick DW, et al; International Headache Society Clinical Trials Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020 Sep;40(10):1026-44. doi: 10.1177/0333102420941839Tfelt-Hansen P, Messlinger K. Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect. Br J Clin Pharmacol. 2019;85:2487-98. doi: 10.1111/bcp.14090Tfelt-Hansen P, Messlinger K. Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect. Br J Clin Pharmacol. 2019;85:2487-98. doi: 10.1111/bcp.14090Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(Suppl 2):S20-6.Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(Suppl 2):S20-6.Salonen R, Scott A. Triptans: do they differ? Curr Pain Headache Rep. 2002;6:133-9. doi: 10.1007/s11916-002-0009-6Salonen R, Scott A. Triptans: do they differ? Curr Pain Headache Rep. 2002;6:133-9. doi: 10.1007/s11916-002-0009-6Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: A novel drug delivery system. Pharma Times. 2003;35:7-9.Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: A novel drug delivery system. Pharma Times. 2003;35:7-9.Ahrens SP, Farmer MV, Williams DL. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19:525-30. doi: 10.1046/j.1468-2982.1999.019005525.xAhrens SP, Farmer MV, Williams DL. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19:525-30. doi: 10.1046/j.1468-2982.1999.019005525.xCady R, Visser WH, Ahrens SP, et al. Longterm efficacy or rizatriptan orally disintegrating tablets for treating intermittent migraine attacks [abstract]. Headache. 2000;40(5):400.Cady R, Visser WH, Ahrens SP, et al. Longterm efficacy or rizatriptan orally disintegrating tablets for treating intermittent migraine attacks [abstract]. Headache. 2000;40(5):400.

The authors declare that there are no conflicts of interest present.